NEO NeoGenomics, Inc.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 38.9% gain over the past six months, beating the S&P 500 by 20.9 percentage points.

What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

NeoGenomics stock reaction to precision oncology expansion plan NeoGenomics (NEO) drew investor attention after executives detailed plans to expand in community-based precision oncology, highlighting next-generation sequencing, minimal residual disease testing, and workflow tools for community physicians as key focus areas. NeoGenomics shares have been on a strong run recently, with a 30-day share price return of 14.31% and a 90-day gain of 69.22%. The 1-year total shareholder return of...

Earlier in 2026, NeoGenomics executives detailed plans to expand in community-based precision oncology, with a particular push into next-generation sequencing, minimal residual disease testing, and workflow tools for community oncologists. An important takeaway is that NGS already represents a relatively small share of test volume but a much larger portion of clinical revenue, underscoring how mix shift toward advanced assays could reshape the company’s earnings profile. We’ll now examine...

NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at t

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high. Shares are up more than 170% over the past 52 weeks. NEO maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and...

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss of US$45.09 million a year earlier. Alongside this return to quarterly profitability and higher six-month revenues, management narrowed expected full-year 2026 net loss to US$42 million–US$34 million and modestly raised its revenue outlook to US$802 million–US$806 million, signaling increased...

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expectations and narrowed projected net loss. See our latest analysis for NeoGenomics. NeoGenomics shares traded at US$15.84 on 31 July 2026, with a 90 day share price return of 78.18% and a 1 year total shareholder return of 181.85%, which points to strong recent momentum despite a weaker 5 year...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 17% over the past six months while the S&P 500 was up 8.3%.

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported second-quarter 2026 earnings that surpassed Wall Street expectations and raised its full-year financial guidance.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and

NeoGenomics Inc (NEO) reports robust revenue growth and margin expansion, while addressing challenges in its pharma segment and raising full-year guidance.

NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing. Total second-quarter revenue rose 11% ye

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on year to $201.7 million. The company expects the full year’s revenue to be around $804 million, close to analysts’ estimates. Its non-GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

NeoGenomics stock has delivered a strong 134.1% return over the past year, yet its current checks suggest the shares may be priced at a premium rather than standing out as a clear bargain. Over the last 1 year, NeoGenomics has returned 134.1%, which puts extra focus on whether the recent enthusiasm is already reflected in the price. The launch of the FDA approved PTEN IHC companion diagnostic for prostate cancer can support expectations for NeoGenomics' testing volumes and commercial reach,...

NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion diagnostic that helps identify prostate cancer patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP. See our latest analysis for NeoGenomics. The FDA-cleared PTEN IHC CDx arrives at a time when NeoGenomics’ share price has shown strong short term momentum, with a 30-day share price return of 40.75% and a 1-year total shareholder return of 134.13%, although the 3- and 5-year total...

Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.